2020 Speaker List By Programs

Display of Antibodies

[KEYNOTE] James Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
Andrew Bradbury, MB BS, PhD, CSO, Specifica, Inc.
Paul Carter, PhD, Senior Staff Scientist & Senior Director, Antibody Engineering, Genentech
Jennifer Cochran, PhD, Shriram Chair of Bioengineering; Professor of Bioengineering, and (by courtesy) Chemical Engineering, Stanford University
M. Frank Erasmus, PhD, Head, Bioinformatics, Specifica, Inc.
Simon Friedensohn, Researcher, Biosystems Science & Engineering, ETH Zurich
Melissa Geddie, PhD, Senior Scientist, Antibody Discovery, Biogen
Tamir Gonen, PhD, Professor, Biological Chemistry and Physiology, David Geffen School of Medicine, University of California, Los Angeles
Andrew Kruse, PhD, Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Jonathan Lai, PhD, Professor, Biochemistry, Albert Einstein College of Medicine
Jennifer Maynard, PhD, Henry Beckman Professor, McKetta Department of Chemical Engineering, Cockrell School of Engineering, The University of Texas at Austin
John McCafferty, PhD, CEO and Founder, IONTAS
Vera Molkenthin, PhD, Chief Scientist, AbCheck
Robert Pejchal, PhD, Director, Antibody Engineering, Adimab LLC
Aaron Ring, MD, PhD, Assistant Professor, Immunobiology, Yale School of Medicine
Nathan Robertson, PhD, Group Leader, Antibody Discovery Team, OXGENE
Jan Steyaert, PhD, Francqui Research Professor, Vrije Universiteit Brussel (VUB); Director, VIB-VUB Center for Structural Biology, VIB
K. Dane Wittrup, PhD, J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technolog
Birgit Viira, Key Account and Technology Officer, Icosagen
Gregory Weiss, PhD, Professor, Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
Gur Yaari, PhD, Associate Professor, Bioengineering, Faculty of Engineering, Bar Ilan University

Engineering Antibodies

[KEYNOTE] David Gifford, PhD, Professor, Computer Science and Biological Engineering, MIT
Nicoletta Bivi, PhD, Director, Assay Development, Immunogenicity and Immunoassays, Laboratory for Experimental Medicine (LEM), Eli Lilly and Company
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular
Brandon DeKosky, PhD, Assistant Professor, Chemical Engineering, University of Kansas
Francois-Thomas Michaud, PhD, CEO, Feldan Therapeutics
Avinash Gill, PhD, Senior Scientific Manager, Genentech
Claes Gustafsson, PhD, Co-Founder and CCO, ATUM
María González Pajuelo, PhD, CSO, FairJourney Biologics
Kevin Heyries, PhD, Co-Founder, Head of Business Development, AbCellera
Philip Kim, PhD, Associate Professor, Molecular Genetics, University of Toronto
Shohei Koide, PhD, Professor, Biochemistry and Molecular Pharmacology, NYU School of Medicine; Perlmutter Cancer Center
Jiwon Lee, PhD, Assistant Professor, Engineering, Dartmouth University
Carlos Reis, PhD, Team Leader Molecular Design and Engineering, GlaxoSmithKline, United Kingdom
Lucie Rochard, PhD, Liaison, Scientific & Entrepreneurial Initiatives; Director, Innovation Services, Massachusetts Biotechnology Council
Julie Su, PhD, Senior Research Investigator, Molecular Discovery Technologies, Bristol-Myers Squibb
Rodrigo Vazquez-Lombardi, PhD, Postdoctoral Fellow, Biosystems Science and Engineering, ETH Zurich, Switzerland
Erik Vernet, PhD, Director, Protein Engineering, Novo Nordisk Research Center Seattle
Sally Ward, PhD, Professor, Molecular Immunology, University of Southampton, United Kingdom

Engineering Bispecific Antibodies

[KEYNOTE] Janice Reichert, PhD, Executive Director, The Antibody Society
[KEYNOTE] Dimitris Skokos, PhD, Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals
Mahiuddin Ahmed, PhD, CSO, Y-mAbs Therapeutics
Tara Arvedson, PhD, Executive Director, Oncology and Inflammation Research, Amgen
Javier Chaparro-Riggers, PhD, Executive Director, Biomedicine Design, Pfizer Inc.
Colin Correnti, PhD, Senior Scientist and Director of Protein Sciences, Fred Hutchinson Cancer Research Center
Jonathan H. Davis, PhD, Head, Innovation, Invenra, Inc.
Stephen Demarest, PhD, Senior Research Fellow, Eli Lilly and Company
John Desjarlais, PhD, CSO, Xencor
Gundo Diedrich, PhD, Director, Antibody Engineering, MacroGenics, Inc.
Takashi Ebihara, PhD, COO, GeneFrontier Corporation
Amanda Fitzgerald, PhD, Senior Scientific Consultant, Biologics, Genedata
Tariq Ghayur, PhD, Distinguished Research Fellow, Foundational Immunology, AbbVie
Mohamad Hamieh, PhD, Research Associate, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Dietmar Hoffmann, PhD, Associate Director, Section Head Molecular, Expression and Screening Technologies Group, Biologics Research US, Sanofi
G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology, Inc.
Nathan Trinklein, PhD, CTO, Discovery, Teneobio
Salvatore Valitutti, MD, Director, Research, INSERM; Head, Laboratory Molecular Dynamics of Lymphocyte Interactions, Cancer Research Center of Toulouse
Zhi Yong Yang, PhD, Director, Synthetic & Immune Biology, Sanofi
Eugene Zhukovsky, PhD, CSO, Biomunex Pharmaceuticals

Antibodies for Cancer Therapy

[KEYNOTE] Pablo Umaña, PhD, Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich (Roche Glycart AG)
Ezio Bonvini, MD, CSO, MacroGenics, Inc.
Donald Buchsbaum, PhD, Professor and Director, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham
Adam Cohen, MD, Assistant Professor, Hematology & Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania
Wafik El-Deiry, MD, PhD, FACP, Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University
Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital
David FitzGerald, PhD, Chief, Biotherapy Section, Laboratory of Molecular Biology, CCR, National Cancer Institute, NIH
Arthur Frankel, MD, Chief, Hematology/Oncology, Mitchell Cancer Institute, University of South Alabama
Terry Fry, MD, Professor of Pediatrics, Hematology and Immunology, University of Colorado
Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH
G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology
Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim
Simon Plyte, PhD, Vice President, Immune Oncology, Merus NV
Ernest Smith, PhD, Senior Vice President, Research, CSO, Vaccinex, Inc.
Cornelis Sier, PhD, Molecular Biologist, Project Leader Targeting, Department of Image-Guided Oncologic Surgery, Leiden University Medical Center
Eric Smith, PhD, Senior Director, Bispecifics, Regeneron Pharmaceuticals
Daniel Vallera, PhD, Lion Scholar and Professor; Director, Section on Molecular Cancer Therapeutics; Professor of Therapeutic Radiology, University of Minnesota Masonic Cancer Center

Advancing Bispecific Antibodies and Combination Therapy to the Clinic

[KEYNOTE] Paul Parren, PhD, Executive Vice President, Head, R&D, Lava Therapeutics B.V.
Ramon Alemany, PhD, Scientist, ProCure and Oncobell Programs, Catalan Institute of Oncology - IDIBELL
Alexey Berezhnoy, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.
Ingmar Bruns, MD, PhD, Vice President, Clinical Development, Pieris Pharmaceuticals GmbH
Alison Crawford, PhD, Senior Staff Scientist, Oncology & Angiogenesis, Regeneron Pharmaceuticals
Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen
Jonny Finlay, PhD, CEO, UltraHuman Ltd.
Nicolas Fischer, PhD, CEO, Light Chain Bioscience, Novimmune SA
Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics
Teemu Junttila, PhD, Principal Scientist, Translational Oncology, Genentech
Jogender Tushir-Singh, PhD, Assistant Professor, Biochemistry & Molecular Genetics, UVA Cancer Center, University of Virginia School of Medicine
Li Peng, PhD, Senior Vice President, Research and Early Product Development, Palleon Pharmaceuticals
Liu Rihe, PhD, Associate Professor, Chemical Biology and Medicinal Chemistry, Eschelman School of Pharmacy, University of North Carolina, Chapel Hill

Clinical Progress of Antibody-Drug Conjugates

[KEYNOTE] Rakesh Dixit, DAPT, PhD, President & CEO, Bionavigen
Adnan Abu-Yousif, PhD, Associate Director, IO Biology, Takeda Pharmaceuticals
Rupert Davies, PhD, Director, Translational Sciences, Zymeworks
Axel Hoos, MD, PhD, Senior Vice President, Oncology R&D, GSK
Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, US FDA
Steven Larson, MD, Head, Larson Lab, Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Bob Lechleider, MD, Senior Vice President, Development, Seattle Genetics
Nancy Levin, PhD, Vice President, Development, Triphase Accelerator
Donald Mager, PharmD, PhD, FCP, Professor & Vice Chair, Pharmaceutical Sciences, University of Buffalo
Charlotte McDonagh, PhD, Vice President, Biotherapeutics, Magenta Therapeutics
Maureen O’Connor-McCourt, PhD, CSO, Forbius
Eben Rosenthal, MD, Cancer Center Medical Director, Otolaryngology, Stanford University
Dhaval Shah, PhD, Associate Professor, Pharmaceutical Sciences, University of Buffalo
Anthony Tolcher, PMP, FRCPC, FACP, Director, Clinical Research, CEO & Founder, Next Oncology
Louis Weiner, MD, Director, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University
Xiaomai Zhou, PhD, Vice President, Biology, Hangzhou DAC Biotech, China

Improving Immunotherapy Efficacy and Safety

[KEYNOTE] Jeffrey Miller, MD, Professor of Medicine, Deputy Director, Masonic Cancer Center, Division of Hematology, Oncology and Transplantation, University of Minnesota
Stewart Abbot, PhD, Senior Vice President, CSO, Adicet Bio
Nick Brown, MSc, North American Business Development Manager, Retrogenix Limited
Sidi Chen, PhD, Assistant Professor, Department of Genetics & Systems Biology Institute, Yale Cancer Systems Biology Center, Yale Center for Biomedical Data Science, Yale University School of Medicine
Benjamin Doranz, PhD, MBA, President, CEO, Integral Molecular
Alex Franzusoff, PhD, CEO, PACT Pharma
Marvin Gee, PhD, Head, Target Discovery, 3T Biosciences
Karin Jooss, PhD, Executive Vice President, Research and CSO, Gritstone Oncology, Inc.
Saad Kenderian, PhD, Assistant Professor, Medicine and Oncology, Mayo Clinic College of Medicine
Hans Klingemann, MD, PhD, Vice President, Research and Development, NantKwest, Inc.
Lawrence Lamb, PhD, CSO, Incysus
Maksim Mamonkin, PhD, Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine
Daniel Olive, MD, PhD, Head Tumor Immunology, Marseillle Cancer Research Center
Laszlo Radvanyi, PhD, President and Scientific Director, Ontario Institute for Cancer Research
James Riley, PhD, Associate Professor, Microbiology, University of Pennsylvania
Conrad Russel Cruz, PhD, Director, Translational Research Laboratories, Center for Emerging Technologies in Immune Cell Therapy, Children’s National Hospital
Norihiro Watanabe, Instructor, Center for Cell and Gene Therapy, Baylor College of Medicine
Travis Young, PhD, Vice President, Biologics, CALIBR, A Division of Scripps Research

CAR Ts, TCRs and TILs

[KEYNOTE] Adrian Bot, PhD, Vice President, Translational Medicine, Kite Pharma, a Gilead Company
[KEYNOTE] Prasad Adusumilli, MD, FACS, FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center; Associate Professor, Cardiothoracic Surgery, Weill Cornell Medical Center
Chantale Bernatchez, PhD, Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Corrine Epperly, MD, MPH, Senior Vice President, Strategy and Operations, Iovance Biotherapeutics
Rajkumar Ganesan, PhD, Director, Antibody Engineering, Bispecifics and CAR T, Janssen
Suzanne Hibbs, MS, MBA, Senior Product Manager, Cell Design Studio, MilliporeSigma
Simon Lacey, PhD, Director, Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies, University of Pennsylvania
Daniel MacLeod, PhD, Senior Director, Cell Therapy Discovery, Precision BioSciences
Paul Neeson, PhD, Associate Professor, Cancer Immunoloy Research, Peter MacCallum Cancer Centre
Laurent Poirot, PhD, Vice President, Immunology, Cellectis
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine
Peggy Sotiropoulou, PhD, Director, Research & Development, Celyad
Tom Van Blarcom, PhD, Head, Protein Engineering, Allogene Therapeutics
Bob Valamehr, PhD, Chief Development Officer, Fate Therapeutics

Agonist Immunotherapy Targets

[KEYNOTE} Axel Hoos, PhD, Senior Vice President, Therapeutic Area Head, Oncology, GSK
Adam Adler, Professor, Department of Immunology, University of Connecticut Health School of Medicine
Peter Ellmark, PhD, Vice President, Discovery, Alligator Bioscience
Fiona Harding, PhD, Senior Research Fellow, Oncology Discovery, AbbVie
Oliver Hill, PhD, Vice President, Molecular Biology, Apogenix
Bruce Keyt, PhD, CSO, IGM Biosciences
Helen Kotanides, PhD, Senior Research Advisor, Cancer Immunobiology, Eli Lilly
Patrick Mayes, PhD, Executive Director, Head, IO Antibody Research, Incyte
Alexander Muik, PhD, Head, Immunomodulators, BioNTech
Dafne Müller, PhD, Group Leader, Institute of Cell Biology and Immunology, University of Stuttgart
William Redmond, PhD, Associate Member and Director, Immune Monitoring Laboratory, Earle A. Chiles Research Institute, Providence Cancer Institute
Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs, Inc.
Elizabeth Trehu, MD, CMO, Jounce Therapeutics
Michael Yellin, MD, Vice President, Clinical Science, Celldex
Bin Zhang, MD, PhD, Professor, Department of Medicine – Division of Hematology/Oncology, Department of Microbiology-Immunology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine

Characterization for Novel Biotherapeutics

[KEYNOTE] Julia Ding, PhD, Director, Process Analytics & Analytical Development, Bristol-Myers Squibb
Yoshiko Akamatsu, PhD, Senior Principal Research Scientist, AbbVie
George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen
Arnd Brandenburg, PhD, Head, Professional Services, Genedata Expressionist, Genedata
Iain Campuzano, Principal Scientist, Discovery Attribute Sciences, Amgen
Cexiong (Winston) Fu, PhD, Principal Scientist, Takeda
Mei Han, Senior Scientist, Pharmacokinetics & Drug Metabolism, Amgen
Soraya Hoelper, PhD, Lab Head Mass Spectrometry, Protein Therapeutics, R&D Biologics Germany, Sanofi-Aventis Deutschland GmbH
Xiaoqing Hua, Senior Scientist, Merck
Sunnie Kim, PhD, Senior Scientist, Seattle Genetics
Kawaljit Kaur, PhD, Associate Researcher, Vaccine Analytics and Formulation Center, Pharmaceutical Chemistry, University of Kansas
Dennis Krieg, PhD, Researcher, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians-University Munich, Germany
Delphine Mathieu, PhD, Head, ADC Analytical Skill Center, Biologics Development Sanofi, France
Wendy Ritacco, Senior Scientist, AbbVie Bioresearch Center
Christina Palmer, Scientist, Antibody Discovery, Biogen
Wendy Sandoval, Principal Scientist, Genentech
Stefan Seeber, PhD, Senior Principal Scientist, Cell Technologies, Roche Pharma Research and Early Development, Germany
Renee Tobias, Director, Marketing, HALO LABS
Ming Zeng, PhD, Associate Director, Parenteral Sciences & Technology Bristol-Myers Squibb

Biophysical Methods

[KEYNOTE] Theodore Randolph, PhD, Professor, Chemical and Biological Engineering, University of Colorado
Marc Bailly, PhD, Associate Principal Scientist, Merck
Björn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Physical Chemical Analytics, Novartis Pharma AG, Switzerland
Stephen D'Eri, Scientist, Sanofi
Stacy Elliot, PhD, Principal Scientist, R&D, RheoSense, Inc.
John Kelly, PhD, Senior Research Officer, Mass Spectrometry, National Research Council Canada
Diana Pippig, PhD, Senior Scientist and Team Lead, Functional Characterization, Roche, Germany
John Rhoden, PhD, Senior Research Scientist, Drug Disposition, Eli Lilly and Company
Gabriel Rocklin, PhD, Assistant Professor, Pharmacology, Northwestern University
Brandon Ruotolo, PhD, Professor, Chemistry, University of Michigan
Peter Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan
Christy Thomson, PhD, Senior Scientist, Research, Amgen
Andrew Urick, PhD, Senior Scientist, AbbVie
Benjamin Walters, PhD, Scientist, Biochemistry and Cellular Pharmacology, Genentech

Cell and Gene Therapy Analytics

[KEYNOTE] Jan Joseph (Jos) Melenhorst, PhD, Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania
Eric Alonzo, PhD, Senior Scientist, bluebird bio
Win Cheung, PhD, Associate Director, Analytical Development, REGENXBIO
Amber Fradkin, PhD, Director, Particle Characterization Core Facility, KBI Biopharma
Martin Jarrold, PhD, Professor, Chemistry, Indiana University
Wim Jiskoot, PhD, Professor, Drug Delivery Technology, Leiden University, The Netherlands
Prashant Kumar, PhD, Senior Scientist, Vaccine Analytics, University of Kansas
Alden Ladd, Scientist, Cellular Process Development, bluebird bio
Lin Liu, PhD, Principal Scientist, Biologics Development, Sanofi
William Motel, PhD, Associate Director, Regulatory Affairs, IQVIA
Michele Perry, Lead Microbiology Associate, Analytical Development, Synlogic
Ken Riker, Director, Product Quality, Celgene
Richard Rustandi, PhD, Principal Scientist, Vaccine Analytical Research Development, Merck
Jean Stanton, Director, CAR-T Site Liaison, Janssen
Dong Xu, PhD, Senior Scientist, Biogen

Difficult-to-Express Proteins

[KEYNOTE] Kurt Wüthrich, PhD, Professor, Biophysics, Institute of Molecular Biology, ETH Zürich
Anirban Adhikari, PhD, Associate Director, Biologics Research, Parvus Therapeutics, Inc.
Elizabeth Brunk, PhD, Scientist, Bioengineering, Moores Cancer Center, University of California, San Diego (UCSD)
Matthew Coleman, PhD, Senior Scientist & Group Leader, Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory
Susanne Gräslund, PhD, Principal Investigator, Structural Genomics Consortium, Karolinska Institute
Arthur Laganowsky, PhD, Assistant Professor, Chemistry, Texas A&M University
James Love, PhD, Director, Applied Automation, Global Research Technologies, Novo Nordisk A/S
Shahram Misaghi, PhD, Senior Scientist, Early Stage Cell Culture (ESCC), Genentech, Inc.
Mahmoud Nasr, PhD, RPh, Group Leader, Medicine, Brigham and Women’s Hospital, Harvard Medical School
Ho Leung Ng, PhD, Associate Professor, Biochemistry & Molecular Biophysics, Kansas State University
Reda Rawi, PhD, Staff Scientist, Structural Bioinformatics Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH)
Anne Skaja Robinson, PhD, Trustee Professor and Head, Chemical Engineering, Carnegie Mellon University
Rana Sidhu, PhD, Protein Expression Lead, Early Solutions, UCB, Inc.
Anupam Singhal, PhD, Technology Development, Berkeley Lights, Inc.
Thariska Tharmakulasingam, Specialist, Orbital Bioreactors, Kuhner Shaker AG
Ian Wilkinson, CSO, Absolute Antibody
Alexei Yeliseev, PhD, Staff Scientist, Group Leader, LMBB, NIH/NIAAA
Xinchao Yu, PhD, Senior Scientist, Molecular Engineering, Amgen, Inc.
Shlomo Zarzhitsky, PhD, Research Associate, Chemistry, Princeton University

Optimizing Protein Expression

[KEYNOTE] Catherine Owczarek, PhD, Director, Recombinant Protein Expression Group, CSL Limited
Imre Berger, PhD, Director, Max Planck Centre for Minimal Biology, the University of Bristol
Richard Cooley, PhD, Research Assistant Professor, Biochemistry and Biophysics, Oregon State University
Hussain Nuruddin Dahodwala, PhD, Associate Site Director, AMBIC, Delaware Biotechnology Institute, University of Delaware
Jan-Willem de Gier, PhD, Professor, Biochemistry and Biophysics, Stockholm University
William Gillette, PhD, Principal Scientist, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
Ingo Gorr, PhD, Director and Head, Early Stage Bioprocess Development (USP&DSP), Boehringer Ingelheim Pharma GmbH & Co. KG
Markus Hildinger, PhD, CEO, evitria AG
Monique Janowski-Egler, PhD, Head of USP, BioProcess Development Halle, BioProcess Development, Wacker Biotech GmbH
Dennis Karthaus, MSc, Director Protein Products & Assays, IBA Lifesciences
Saleha Patel, PhD, Senior Research Scientist, Protein Science, Discovery Biology, AstraZeneca
Theodore Peters, PhD, Senior Scientist, Cell Line Development Group, Seattle Genetics, Inc.
Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine
Susan Sharfstein, PhD, Professor, Nanobioscience, Nanoscale Science and Engineering, SUNY Polytechnic Institute
Gerald Striedner, PhD, Associate Professor, University of Natural Resources and Life Sciences, Vienna (BOKU)
Johannes van den Heuvel, PhD, Research Group Leader, Structure and Function of Proteins, RG Recombinant Protein Expression, Helmholtz Centre for Infection Research

Protein Expression System Engineering

[KEYNOTE] Joshua LaBaer, MD, PhD, Executive Director & Professor, Molecular Sciences, BioDesign Institute, Arizona State University
Amr Ali, PhD, Scientist, Technical Development, Biogen
William Chen, MD, PhD, Research Scientist, Electronics and Biological Engineering, Massachusetts Institute of Technology (MIT)
Zhenling Cui, PhD, CTCB, Research Associate, Science and Engineering, Chemistry, Physics, Mechanical Engineering, Energy and Process Engineering, Queensland University of Technology (QUT)
Kim De Keersmaecker, PhD, Research Professor, Oncology – Laboratory for Disease Mechanisms in Cancer, Katholieke Universiteit Leuven
Chester Drum, MD, PhD, Assistant Professor, Translational Innovation, National University of Singapore
Zhimei Du, PhD, Director, Process Development, Merck and Co., Inc.
Chava Kimchi-Sarfaty, PhD, Deputy Associate Director for Research, Office of Tissues and Advanced Therapies, CBER, FDA
John LaCava, PhD, Group Leader, Laboratory of Macromolecules and Interactomes, European Research Institute for the Biology of Aging, University Medical Center Groningen
Fides Lay, PhD, Scientist, Cell Line Development & Genetic Characterization, Amgen, Inc.
Nathan Lewis, PhD, Associate Professor, Pediatrics, University of California, San Diego (UCSD)
Julija Mezhyrova, MSc, Scientist, Institute of Biophysical Chemistry, Goethe University
Idris Mustafa, MS, Lead Automation Scientist, BioMolecular Resources, Genentech, Inc.
Samuel Sternberg, PhD, Assistant Professor, Biochemistry and Molecular Biophysics, Columbia University
Yizhou Zhou, PhD, Scientist II, Cell Line Development, Biogen

Immunogenicity Case Studies and Clinical Management

[KEYNOTE] Priya Sunil Kishnani, MBBS, Chen Family Professor of Pediatrics, Chief, Medical Genetics, Molecular Genetics and Microbiology, Duke University
Johanna Abend, Senior Scientist I, Immunogenicity, Translational Sciences, BioMarin Pharmaceutical, Inc.
Nicoletta Bivi, PhD, Director, Assay Development, Laboratory of Experimental Medicine, Eli Lilly
Sandra Garces, MD, PhD, Clinical Research Director, Global Drug Development, Amgen
Jochem Gokemeijer, PhD, Associate Director, Molecular Discovery Technologies, Bristol-Myers Squibb
Kristin Hollister, PhD, Senior Research Scientist, Clinical Advisory Group, Laboratory for Experimental Medicine, Eli Lilly and Company
Vibha Jawa, PhD, Director and Lead, Predictive and Clinical Immunogenicity, PPDM, Merck & Co., Inc.
Brian Long, PhD, Associate Director, Immunogenicity Assessment, BioMarin Pharmaceutical, Inc.
Jim McNally, PhD, Executive Director, Head of Research and Clinical Assays, Program Lead, CRISPR Therapeutics
Erik Meyer, PhD, Investigator, Bioanalysis, Immunogenicity and Biomarkers (BIB), IVIVT, R&D, GlaxoSmithKline
Mark Milton, PhD, Executive Director, PK Sciences, Global Head Ophthalmology TA, Novartis Institutes for BioMedical Research, Inc.
Pedro Paz, PhD, Director, Principal Scientist, ImmunoProfiling Group in Biologics Research, Bayer Healthcare
Kate Peng, PhD, Group Leader/Senior Scientist, BioAnalytical Sciences, Genentech
Yariv Wine, PhD, Assistant Professor, Molecular Cell Biology and Biotechnology, Tel Aviv University, Israel

Immunogenicity Assessment and Regulatory Approval of Biologics

Sivan Cohen, PhD, Scientist, BioAnalytical Sciences, Genentech
Boris Gorovits, PhD, Senior Director, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc.
Timothy Hickling, PhD, Immunogenicity Sciences Lead, Pfizer Inc.
Wojciech Jankowski, PhD, Biologist, Center for Biologics, Evaluation and Research / Office of Tissues and Advanced Therapies, FDA
Hao Jiang, PhD, Principal Scientist, Bioanalytical Sciences, Bristol-Myers Squibb
Leopold Kong, PhD, Chemist, Product Quality Reviewer, Biotechnology Review & Research IV, Office of Biotechnology Products, OPQ, CDER, FDA
Ching-Ha (Vicky) Lai, PhD, Senior Staff Scientist, Bioanalytical Sciences, Regeneron Pharmaceuticals, Inc.
Zhenzhen Liu, PhD, FDA/CDER/OPQ/Office of Biotechnology Products, FDA
Kelli Phillips, PhD, MBA, Laboratory Manager, PPD® Laboratories
Alessandro Sette, Dr. Biol. Sci., Professor, Head and Member, La Jolla Institute for Immunology
Megan Wiberg, Laboratory Manager, PPD® Laboratories
Weifeng Xu, PhD, Principal Scientist, PPDM, Regulated Immunogenicity and Molecule, Merck

Optimizing Bioassays for Biologics

[KEYNOTE] Marla Abodeely, PhD, Director, Bioassay, Global MSAT Analytical Science and Technology, Sanofi
Jen Fox, PhD, Scientist, Bioassay, Impurities, and Quality, Analytical Sciences, AstraZeneca
Dawn Henke, PhD, Senior Technical Program Manager, Standards Coordinating Body
David Lansky, PhD, President, Precision Bioassay, Inc.
Thomas Little, PhD, President and CEO, Bioassay Sciences, Thomas A. Little Consulting
Lisa Lundberg, Bioassay and Cell Culture Lead, Spark Therapeutics
Natalia Kozhemyakina, Head, Bioassay Department, BIOCAD
Carole Sourbier, PhD, Principal Investigator, Office of Biotechnology Products, US FDA
Valeria Runza, PhD, Head, Functional Characterization, Large Molecules Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH
Sumona Sarkar, PhD, Biomedical Engineer, Biosystems and Biomaterials Division, Biomaterials Group, National Institute of Standards and Technology
Timothy Schofield, Owner and Consultant, CMC Sciences, LLC
Steven Walfish, MBA, Principal Scientific Liaison, USP
Kun Yang, PhD, Associate Principal Scientist, PPDM, Merck
Junming Yie, PhD, Principal Scientist, Cell Based Assays, Biologics AR&D, Merck Research Laboratories

Engineering Antibody-Drug Conjugates

[KEYNOTE] Greg Thurber, PhD, Associate Professor, Chemical Engineering and Biomedical Engineering, University of Michigan
Greg Adams, PhD, CSO, Elucida Oncology, Inc.
Gonçalo Bernardes, DPhil, Reader (Associate Professor), Chemical Biology, University of Cambridge
Mahendra Deonarain, PhD, Chief Executive and Science Officer, Antikor Biopharma, Ltd.
Ulf Grawunder, PhD, CEO, NBE Therapeutics
Torsten Hechler, PhD, Vice President, ADC Research, Biochemistry, Heidelberg Pharma
Peter Hudson, FTSE, PhD, Chief Scientist and CSO, Avipep Pty Ltd.
Shou-Ching Jaminet, PhD, Founder & Head of Research, Angiex, Inc.
Amit Kumar, PhD, Scientist I, Antibody Discovery and Protein Engineering, AstraZeneca
Robert Lutz, PhD, CSO, Iksuda
Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich)
Anton Neschadim, PhD, MBA, CEO, ImmunoBiochem Corporation
Siew Schleyer, PhD, Director, Oncology Research, CytomX Therapeutics
Philipp Spycher, PhD, CEO, Araris Biotech AG

Clinical Progress of Antibody-Drug Conjugates

[KEYNOTE] Rakesh Dixit, DAPT, PhD, President & CEO, Bionavigen
Adnan Abu-Yousif, PhD, Associate Director, IO Biology, Takeda Pharmaceuticals
Rupert Davies, PhD, Director, Translational Sciences, Zymeworks
Axel Hoos, MD, PhD, Senior Vice President, Oncology R&D, GSK
Wen Jin Wu, MD, PhD, Senior Investigator, Office of Biotechnology Products, US FDA
Steven Larson, MD, Head, Larson Lab, Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Bob Lechleider, MD, Senior Vice President, Development, Seattle Genetics
Nancy Levin, PhD, Vice President, Development, Triphase Accelerator
Donald Mager, PharmD, PhD, FCP, Professor & Vice Chair, Pharmaceutical Sciences, University of Buffalo
Charlotte McDonagh, PhD, Vice President, Biotherapeutics, Magenta Therapeutics
Dhaval Shah, PhD, Associate Professor, Pharmaceutical Sciences, University of Buffalo
Maureen O’Connor-McCourt, PhD, CSO, Forbius
Eben Rosenthal, MD, Cancer Center Medical Director, Otolaryngology, Stanford University
Anthony Tolcher, PMP, FRCPC, FACP, Director, Clinical Research, CEO & Founder, Next Oncology
Louis Weiner, MD, Director, Oncology, Lombardi Comprehensive Cancer Center, Georgetown University
Xiaomai Zhou, PhD, Vice President, Biology, Hangzhou DAC Biotech, China

Emerging Indications for Therapeutic Antibodies

[KEYNOTE] Madhusudan Natarajan, PhD, Head, Rare Diseases DDU, Takeda
Claire Harris, PhD, Professor, Molecular Immunology, Newcastle University, United Kingdom
Robert Giugliano, MD, MSc, Associate Professor, Medicine, Harvard Medical School
Charles Glabe, PhD, Professor, Molecular Biology and Biochemistry, University of California, Irvine
Benjamin Hackel, Associate Professor, Chemical Engineering and Materials Science, University of Minnesota
JT Koerber, PhD, Senior Scientist, Antibody Engineering, Genentech
Greg Lazar, PhD, Director and Senior Scientist, Antibody Engineering, Genentech
Elissa Leonard, PhD, Postdoctoral Fellow, Biomedical Engineering, Johns Hopkins University
Yang Li, PhD, Vice President, Biology, Surrozen Inc.
Michael McPherson, PhD, Senior Principal Research Scientist, Discovery Biologics, AbbVie
Jens Niewoehner, PhD, Senior Principal Scientist, Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Germany
Sarav Rajan, PhD, Senior Scientist, AstraZeneca R&D
Philipp Scherer, PhD, Professor, Internal Medicine, UT Southwestern
Eric Shusta, PhD, Professor, Chemical and Biological Engineering, University of Wisconsin-Madison
Bas van der Woning, PhD, Research Fellow, arGEN-X, Belgium
Mei-Yun Zhang, PhD, Principal Scientist, Antibody Discovery, Amgen, China

Gene Therapy

[KEYNOTE] Mike Singer, PhD, Medical Officer, Division of Clinical Evaluation and Pharmacology/Toxicology, Center for Biologics Evaluation and Research, FDA
Alex Bloom, PhD, Vice President, Regulatory Affairs and Quality Assurance, RA and QA, Gyroscope Therapeutics
Carlo Boutton, PhD, Head, Nanobody Explorative Technologies, Ablynx, a Sanofi company
Phillip Carter, Head, U.S. Market Access, Orchard Therapeutics
John Champage, Northeast Regional Manager, Senior Applications Scientist, Wyatt Technology
Thomas Gaj, PhD, Assistant Professor, Bioengineering, University of Illinois
Asa Hatami, PhD, Scientist II, Sangamo
Juan Hernandez Bort, PhD, Head, Gene Therapy Technologies, Takeda Austria
Seokjoong Kim, PhD, Executive Director, R&D Strategy and Strategic Alliances, ToolGen
Brenda Laster, PhD, Professor, Nuclear Engineering, Ben-Gurion University
Johnathan Mehtala, Field Application Scientist, Malvern Panalytical
Carl Morris, PhD, CSO, Solid Biosciences
Knut Niss, PhD, CTO, Mustang Bio
Gabriele Proetzel, PhD, Director, External Neuroscience Innovation, Neuroscience Drug Discovery Unit, Takeda Pharmaceuticals
Thomas Raj, PhD, Assistant Professor, Bioengineering, University of Illinois
Yuan Zhao, PhD, Principal Scientist, Leader of Gene Therapy Section, Advanced Therapy Division/NIBSC, Medicines & Healthcare Products Regulatory Agency

Training Seminars Instructors

Mahiuddin Ahmed, PhD, Chief Scientific Officer, Y-mAbs Therapeutics
David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
Regis Cebe, MSc, Scientific Technical Leader, Novartis Biologic Center, NIBR, Novartis Pharma AG, Switzerland
Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
Brandon DeKosky, PhD, Assistant Professor, Department of Chemical Engineering, Department of Pharmaceutical Chemistry, Kansas Vaccine Institute, The University of Kansas
Matías Gutiérrez González, PhD, Postdoctoral Researcher, Pharmaceutical Chemistry, The University of Kansas
Thomas Little, PhD, President and CEO, Bioassay Sciences, Thomas A. Little Consulting
Serguei Kozlov, PhD, MBA, PMP, Principal Scientist/PM, Team Leader Preclinical Technology and Optimization Team, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)
Sheila Magil, PhD, Managing Director, Industry Specialized Services, BDO
Sofie Pattijn, CTO, ImmunXperts
G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology, Inc.
Frank Riske, PhD, Managing Director, Industry Specialized Services, BDO
Bonnie Rup, PhD, Independent Consultant
Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, Inc., a Miltenyi Biotec Company
Traian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, National Research Council Canada

Short Course Instructors:

Omar Abudayyeh, PhD, McGovern Fellow, McGovern Institute for Brain Research, MIT
Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston
Richard Altman, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
Tara Arvedson, PhD, Director, Oncology Research, Amgen
Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
Ramakrishna Boyanapalli, PhD, Associate Director, Bioanalytical and Biomarker Development, Wave Life Sciences
Juan Carlos Almagro, PhD, Founder and CEO, GlobalBio, Inc.
Christine Chan, PhD, Director, Global Manufacturing Science & Technology, Sanofi
Linzhi Chen, Senior Research Fellow & Bioanalytical Group Leader, Boehringer Ingelheim Pharmaceuticals
Daron Forman, PhD, Principal Scientist, Molecular Discovery Technologies, Bristol-Myers Squibb
Tony Christopeit, PhD, Research Scientist, Roche
Claire Davies, PhD, Associate Vice President, Bioanalytics, Sanofi
Nimish Gera, PhD, Director, Research and Development, Mythic Therapeutics
Scott Gerber, PhD, Assistant Professor, Co-Director, Center for Tumor Immunology Research, Surgery, Microbiology, Immunology, Radiation Oncology, University of Rochester Medical Center
Jonathan Gootenberg, PhD, Fellow, McGovern Institute, MIT
Darshana Jani, MS, Associate Director, Pfizer Inc.
Maura Kibbey, PhD, Senior Scientific Fellow, Education & Training, Global Biologics, USP
Francis Poulin, PhD, Director, Analytical Development, Sanofi
Aleksandr Kovaltsuk, MSc (Glas.), DPhil Student, Oxford Protein Informatics Group, Department of Statistics, University of Oxford
Seema Kumar, PhD, Associate Director, Quantitative Pharmacology & Drug Disposition (QPD), R&D Global Early Development (GED), EMD Serono
Liming Liu, PhD, Senior Vice President, Curon Biopharmaceuticals, China
Robert Lutz, PhD, CSO, Iksuda Therapeutics
Jad Maamary, PhD, Associate Principal Scientist, Predictive and Clinical Immunogenicity, PPDM, Merck & Co. Inc.
Matthew Raybould, MChem (Oxon.), DPhil Student, Oxford Protein Informatics Group, Department of Statistics, University of Oxford
Khalid Shah, MS, PhD, Director, Center for Stem Cell Therapies and Imaging, Harvard Medical School; Vice Chair of Research, Brigham and Women’s Hospital
An Song, PhD, Senior Vice President, Development Sciences, Immune-Onc Therapeutics, Inc.
Clifford Steer, MD, Professor of Medicine and Genetics, Cell Biology, and Development; Director, Molecular Gastroenterology Program, University of Minnesota Medical School
Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL); Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
RJ Tesi, MD, CEO, CMO, INmune Bio
Perry Wang, PhD, Research Chemist, US Food and Drug Administration (FDA)
Steven Walfish, MBA, Principal Scientific Liaison, USP